CAH

$207.83-3.09 (-1.47%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Cardinal Health, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$207.83
Potential Downside
76%
Whystock Fair Value$49.79
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Distribution

Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company prov...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$48.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.95
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-54.13%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.44

Recent News

Zacks
Mar 20, 2026

Cardinal Health (CAH) Stock Moves -1.47%: What You Should Know

Cardinal Health (CAH) concluded the recent trading session at $207.83, signifying a -1.47% move from its prior day's close.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 20, 2026

Here's Why You Should Retain AMN HealthCare Stock in Your Portfolio

AMN rides MSP momentum, AI investments and surging labor disruption demand, but pricing pressure and volatile healthcare trends cloud its near-term outlook.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 20, 2026

What Powers BWXT's Strength in Nuclear Medicine Manufacturing?

BWX Technologies expands beyond defense, boosting nuclear medicine with isotopes, new capabilities and a growing role in cancer diagnostics and treatment.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 20, 2026

GEHC Acquires Intelerad to Boost Cloud-First, AI Imaging Capabilities

GE HealthCare completes the $2.3B Intelerad deal to expand AI-driven imaging, boost recurring revenues and strengthen its cloud-first healthcare platform.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 20, 2026

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.